BC Innovations | Nov 2, 2016
Distillery Therapeutics


INDICATION: Alzheimer disease (AD); progressive supranuclear palsy (PSP) Patient sample, cell culture and mouse studies suggest inhibiting NUAK1 could help treat AD, PSP and other tauopathies. In postmortem samples of tau -enriched brain fractions from...
BC Innovations | Aug 28, 2014
Cover Story

Overcoming ibrutinib resistance

Imbruvica ibrutinib's unprecedented response rate in mantle cell lymphoma is generating excitement around the new drug, but as with many targeted cancer therapies, tumors can ultimately become resistant. A recent study from Weill Cornell Medical...
BC Week In Review | Apr 21, 2014
Clinical News

Onconova Therapeutics preclinical data

In a mouse xenograft model of MCL, once-daily 100 mg/kg ON 123300 inhibited tumor growth with "little evidence of toxicity." In a mouse xenograft model of MM, 100 mg/kg ON 123300 given every other day...
BC Innovations | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer NUAK family SNF-like kinase 1 (NUAK1; ARK5); c-Myc (MYC) Mouse and cell culture studies suggest inhibiting ARK5 could help treat MYC-driven cancers. In a...
Items per page:
1 - 4 of 4